On March 5, 2024 AffyImmune Therapeutics, Inc., a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, reported that it will present an abstract in a poster session at the 2024 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, held April 5-10, 2024, in San Diego, California (Press release, AffyImmune Therapeutics, MAR 5, 2024, View Source [SID1234640835]). Presented findings will highlight research applying the affinity-tuned, trackable, ICAM-1 targeting CAR T cell therapy AIC100 to additional solid tumor types where there is significant unmet medical need.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the poster presentation are as follows:
Poster Title: AIC100 CAR-T cells targeting ICAM-1 are efficacious against solid tumors in xenograft mouse models of Non-Small Cell Lung Cancer (NSCLC) and Cervical Cancer (CC).
Date and Time: Tuesday Apr 9, 2024, 9:00 AM – 12:30 PM
Presenting Author: Alyssa Birt, AffyImmune Therapeutics
Session Category: Immunology
Session Title: Adoptive Cell Therapies 3: CAR-T Cells
Location: Poster Section 2, Poster Board Number: 16
Published Abstract Number: 4007